Bryostatin 1 and Rituximab in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

This study has been completed.
Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:

1		Conditions listed in this trial
			Leukemia
			Lymphoma
2		Additional conditions recognized in this trial
			Leukemia, B-Cell
			Leukemia, Lymphocytic, Chronic, B-Cell
			Leukemia, Lymphoid
			Lymphoma, B-Cell
			Lymphoma, Non-Hodgkin
3		More general conditions related to this trial
			Immune System Diseases
			Immunoproliferative Disorders
			Lymphatic Diseases
			Lymphoproliferative Disorders
			Neoplasms
			Neoplasms by Histologic Type
4		Interventions listed in this trial
			bryostatin 1
			rituximab
5		More general drug interventions related to this trial
			Adjuvants, Immunologic
			Antineoplastic Agents
			Antirheumatic Agents
			Immunologic Factors
			Pharmacologic Actions
			Physiological Effects of Drugs
			Therapeutic Uses
6		Sponsors listed in this trial
			National Institute on Aging (NIA)
			National Cancer Institute (NCI)